Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence

University of Tennessee

Status: Enrolling

Conditions: Multiple Myeloma; Multiple Chronic Conditions; Chronic Myeloid Leukemia; Chronic Lymphocytic Leukemia

Treatments: Other: Pharmacist communication; Other: Patient-reported outcome measure; Other: Comprehensive Medication Review

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT04663100

20-0839

Details and patient eligibility

About

The objective of this study is to improve medication, symptom, and disease management of patients with hematological malignancies and multiple chronic conditions (2 or more conditions in addition to cancer) through care coordination between pharmacists working in oncology practices and those working in primary care or community practices (Pharmacists Coordinated care Oncology Model [PCOM]).

This is a pilot study in which the investigators will examine the association between outcome measures, but the study design and sample size are insufficient to quantify the impact of OAA initiation or OAA adherence on adherence to chronic medications. This pilot study and data analyses are being done in preparation for a larger, controlled study.

Enrollment: 30 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Receiving cancer care at Vanderbilt University Medical Center
• Diagnosis of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), chronic myeloid leukemia (CML), or multiple myeloma (MM)
• Initiating an oral anticancer agent, either for the first time or a change from previous oral agent
• Diagnosis of 2 chronic conditions, including at least one of the following: diabetes, hypertension, hyperlipidemia, congestive heart failure, depression/anxiety, gastroesophageal reflux disease, and/or chronic obstructive pulmonary disease
• Patients taking at least two chronic medications, including at least one medication for one of the conditions listed above.
• Willing and able to sign informed consent.

Exclusion criteria

• Cannot communicate in English
• Concurrent diagnosis of type 1 diabetes or human immunodeficiency virus

Trial design

Primary purpose: Health Services Research

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

30 participants in 1 patient group

Pharmacist Coordinated care Oncology Model

Experimental group

Description:

The Pharmacist Coordinated care Oncology Model includes patient self-reported symptoms and medication adherence, comprehensive medication review(s) and intentional communication between oncology and community pharmacists.

Treatment:

Other: Pharmacist communication

Other: Comprehensive Medication Review

Other: Patient-reported outcome measure